Atlas One · Host Biology · Scale 07 — System

Graft-Versus-Host Disease

GvHD occurs when donor T cells recognize host alloantigens after allogeneic HSCT; acute (skin, gut, liver, <100 days) vs. chronic (fibrotic, >100 days). IL-10/Treg axis is protective; ruxolitinib (JAK1/2) is the approved steroid-refractory treatment.

Also known as: GvHD, graft versus host disease, GVHD, acute GvHD, chronic GvHD, aGvHD, cGvHD

Scale 07 — SystemScale
draftStatus
2026-06-07Last Reviewed
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
gvhd

Graft-Versus-Host Disease

GvHD occurs when donor T cells recognize host alloantigens after allogeneic HSCT; acute (skin, gut, liver, <100 days) vs. chronic (fibrotic, >100 days). IL-10/Treg axis is protective; ruxolitinib (JAK1/2) is the approved steroid-refractory treatment.

Entry Metadata

FieldValue
IDgvhd
NameGraft-Versus-Host Disease
Statusdraft
Last reviewed2026-06-07
Atlas01-human
Scale07-system

Cross-Atlas Connections

connects-toIl 10 connects-toBone Marrow connects-toIl 6 connects-toT Helper Cell connects-toT Cytotoxic Cell connects-toGut Microbiome

Sources